No Data
Tasly Pharmaceutical Group (600535.SH): Subsidiary obtains pharmaceutical registration certificate.
On December 4th, Tasly Pharmaceutical Group (600535.SH) announced that its wholly-owned subsidiary Jiangsu Tasly Pharmaceuticals Co., Ltd. (referred to as "Jiangsu Diyi") received the "Pharmaceutical Registration Certificate" approved and issued by the National Medical Products Administration for Paracetamol Oral Solution. According to the product instructions, Paracetamol Oral Solution is indicated for severe but reversible muscle spasms caused by multiple sclerosis, and may have certain efficacy on spasms caused by infectious, degenerative, traumatic, tumorous, or spinal diseases of unknown etiology.
Tasly Pharmaceutical Group (600535.SH) announced a third quarter equity distribution for 2024: a dividend of 0.07 yuan per share with the record date of December 5th.
Tasly Pharmaceutical Group (600535.SH) released the announcement for the distribution of equity for the third quarter of 2024, and this profit distribution is based on the plan...
Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Tasly Pharmaceutical Group: Some products are priced down, leading to a decrease in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Straight to the earnings conference
① Due to the overall low prosperity in the pharmaceutical commerce industry, the company's revenue in this sector declined in the third quarter of this year; although revenue in the pharmaceutical industry sector grew year-on-year, the price reduction of some products led to a decrease in gross margin, and the company expects that the gross margin may remain stable in the future. ② Regarding the equity trade matter of the company's major shareholder with china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting the various aspects of this trade.
Clinical results did not meet expectations. Tasly Pharmaceutical Group suspends the eight-year development "marathon" of the new anti-cancer drug | Summary of the announcement.
① Tasly Pharmaceutical Group announced the suspension of the research and development of its anmeimu monoclonal antibody. Since its approval in 2016, the drug has reached the IIb phase of clinical research; ② According to the clinical research results, the efficacy of anmeimu monoclonal antibody did not meet expectations, and other EGFR monoclonal antibody biosimilar drugs face fierce competition; ③ This project also involves Sino Biopharmaceutical's equity participation, with Tasly Pharmaceutical Group and Sino Biopharmaceutical respectively recognizing an impairment loss of 0.162 billion yuan and 14.1448 million yuan in assets.
tasly pharmaceutical group (600535.SH): Suspended clinical trials of Anmumumab.
On November 22, Gelonghui reported that Tasly Pharmaceutical Group (600535.SH) announced that its holding subsidiary, Tasly Biomedical Co., Ltd., and its holding subsidiary, Shanghai Saiyuan Biotechnology Co., Ltd., have developed a recombinant fully human anti-EGFR monoclonal antibody injection (referred to as "Anmei Muku Antibody") which is currently in phase II clinical trials. Based on the recent conclusions of the "Phase IIb Clinical Research Report (interim analysis)," the company organized external experts and internal pharmaceutical product innovation research and development decision-making committee to conduct technical and market analysis, carefully considering various uncertainties such as the risks of subsequent research and development investments and the commercial market prospects.
No Data
